A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US

References

• National Cancer Institute. Cancer stat facts: colorectal cancer. Bethesda, MD: National Cancer Institute; 2017. Available at: https://seer.cancer.gov/statfacts/html/colorect.html [Accessed April 9, 2018.]
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer. National Comprehensive Cancer Network: Fort Washington, PA; 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. [Accessed August 20, 2018.]
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. [Accessed August 20, 2018.]
   Google Scholar
• Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023–34
   PubMed Web of Science ®Google Scholar
• Shaib W, Mahajan R, El-Rayes B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol 2013;4:308–18
   PubMedGoogle Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240–7
   PubMed Web of Science ®Google Scholar
• Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 2017;32:1179–90
   PubMed Web of Science ®Google Scholar
• Vectibix® (panitumumab). Full Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2016
   Google Scholar
• Carrato A, Abad A, Massuti B, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET-TTD). Eur J Cancer 2017;81:191–202
   PubMed Web of Science ®Google Scholar
• Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009;27:1829–35
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol 2011;11:139
   PubMed Web of Science ®Google Scholar
• Parikh RC, Du XL, Morgan RO, et al. Patterns of treatment sequences in chemotherapy and targeted biologics for metastatic colorectal cancer: findings from a large community-based cohort of elderly patients. Drugs Real World Outcomes 2016;3:69–82
   PubMedGoogle Scholar
• IBM Corporation. Micromedex^®: Red Book Online. Greenwood Village, CO: Thomas Reuters; 2017. Available at: www.micromedexsolutions.com [Last accessed April 9, 2018]
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule search. Baltimore, MD: Centers for Medicare & Medicaid Services; 2017. Available at: http://www.cms.gov/apps/physician-fee-schedule. [Accessed April 9, 2018.]
   Google Scholar
• Data on file. PEAK [NCT00819780] clinical study report. Thousand Oaks, CA: Amgen Inc.; 2013
   Google Scholar
• Palmetto GBA. Medicare 2014 MoPath Tier 2 Fee Schedule, CPT code 81404 (NRAS) reimbursement rate. 2014. Available at: https://protect-eu.mimecast.com/s/TKLfCQ0JMiQnOg9SP-n3Z?domain=palmettogba.comhttps://www.palmettogba.com/palmetto/moldx.nsf/DocsCatHome/MolDx. [Last accessed 2018]
   Google Scholar
• US Department of Labor. Bureau of Labor Statistics: Consumer price index- all urban consumers. Item: medical care. US Department of Labor: Washington, DC; 2017. Available at: https://www.bls.gov/data/. [Accessed April 17, 2018.]
   Google Scholar
• Burudpakdee C, Zhao Z, Munakata J, et al. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies. J Med Econ 2012;15:371–7
   PubMedGoogle Scholar
• Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract 2012;8:75s–80s
   PubMedGoogle Scholar
• Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007;45:1162–70
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ortendahl JD, Purdum AG, et al. Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States. Am J Clin Oncol 2018;41:65–72
   PubMed Web of Science ®Google Scholar
• Data on file. EQ-5D data from the PRIME trial [NCT00364013]. Thousand Oaks, CA: Amgen Inc; 2013
   Google Scholar
• Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–13
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nordlinger B, Cervantes A, et al. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 2010;21(suppl 5):v93–7
   PubMedGoogle Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine: report of the Panel on Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996
   Google Scholar
• Graham CN, Hechmati G, Hjelmgren J, et al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 2014;50:2791–801
   PubMed Web of Science ®Google Scholar
• Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009;27:2111–3
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796–7
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT, Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349–56
   PubMed Web of Science ®Google Scholar
• Ubel PA, Berry SR, Nadler E, et al. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Aff (Millwood) 2012;31:709–17
   PubMed Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90–5
   PubMed Web of Science ®Google Scholar
• Finek J, Skoupa J, Jandova P. [Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer–Czech Republic model adaptation]. Klin Onkol 2015;28:265–72
   PubMedGoogle Scholar
• Rivera F, Valladares M, Gea S, et al. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. J Med Econ 2017;20:574–84
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:1346–55
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Data on file. [Last accessed 2016]
   Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065–75
   PubMed Web of Science ®Google Scholar
• Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017;28:1713–29
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 2017;317:2392–401
   PubMed Web of Science ®Google Scholar